Olema Pharmaceuticals will participate in three investor conferences in New York in September 2026. The company will hold fireside chats at the Citi 2026 Biopharma Back to School Conference on Sept. 10 at 1 p.m. ET, Morgan Stanley’s 24th Annual Global Healthcare Conference on Sept. 15 at 1:50 p.m. ET, and H.C. Wainwright’s 28th Annual Global Investment Conference on Sept. 16 at 9:30 a.m. ET. Live webcasts and recordings will be posted in the Events and Presentations section of Olema’s investor-relations website when permitted by the event hosts. Olema is advancing palazestrant, an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, in two Phase 3 trials, while OP-3136 is in a Phase 1 study.